{
    "nctId": "NCT00932373",
    "briefTitle": "A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen",
    "officialTitle": "A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Trastuzumab-MCC-DM1 (PRO132365) Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "Percentage of Participants With Adverse Events (AE), Serious Adverse Events (SAE), AEs With Grade >=3, and AEs Related To Treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented, incurable, locally advanced or metastatic breast cancer\n* Evaluable or measurable HER2-positive disease\n* History of progression during or within 60 days after treatment with any prior trastuzumab-containing chemotherapy regimen for HER2-positive breast cancer\n* Previous treatment with chemotherapy for MBC\n* Granulocyte count \u2265 1,500/\u03bcL, platelet count \u2265 100,000/\u03bcL, and hemoglobin \u2265 9 g/dL\n* Serum bilirubin \u2264 1.5 mg/dL; AST, ALT, and alkaline phosphatase \u2264 2.5 \u00d7 upper limit of normal (ULN) except for: Patients with hepatic metastases: ALT and AST \u2264 5 \u00d7 ULN Patients with hepatic and/or bone metastases: alkaline phosphatase \u2264 5 \u00d7 ULN\n* Serum creatinine \u2264 1.5 mg/dL or creatinine clearance of \u2265 60 mL/min based on a 24-hour urine collection\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n* Women of childbearing potential and men must agree to use an effective method of birth control (e.g., hormonal, barrier) while receiving study treatment\n\nExclusion Criteria:\n\n* History of significant cardiac disease, unstable angina, CHF, myocardial infarction, or ventricular arrhythmia requiring medication\n* History of Grade \u2265 3 hypersensitivity reaction to trastuzumab\n* History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued\n* Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first study treatment\n* Require supplemental oxygen for daily activities\n* Grade \u2265 2 peripheral neuropathy\n* Bisphosphonate therapy for symptomatic hypercalcemia\n* Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy for the treatment of breast cancer within 4 weeks of first study treatment\n* Any experimental therapy within 4 weeks of first study treatment\n* Any major surgical procedure within 4 weeks of first study treatment\n* History of clinically symptomatic liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis\n* Pregnancy or lactation\n* Cardiac troponin I \u2265 0.2 ng/mL\n* Ejection fraction \\< 50% or below the lower limit of normal determined by echocardiogram or MUGA scan\n* Prior cumulative doxorubicin dose of \\> 360 mg/m2 or equivalent",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}